WuXi AppTec Co. Ltd. Sells 291,446 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)

WuXi AppTec Co. Ltd. decreased its holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 3.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 7,390,710 shares of the company’s stock after selling 291,446 shares during the period. Lyell Immunopharma makes up about 53.6% of WuXi AppTec Co. Ltd.’s portfolio, making the stock its biggest position. WuXi AppTec Co. Ltd. owned about 2.89% of Lyell Immunopharma worth $10,199,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of LYEL. ProShare Advisors LLC increased its position in Lyell Immunopharma by 9.3% during the 1st quarter. ProShare Advisors LLC now owns 48,986 shares of the company’s stock worth $109,000 after purchasing an additional 4,170 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of Lyell Immunopharma in the 1st quarter valued at $173,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Lyell Immunopharma by 1.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,731,477 shares of the company’s stock valued at $15,013,000 after acquiring an additional 92,594 shares in the last quarter. Caxton Associates LP boosted its holdings in shares of Lyell Immunopharma by 359.1% during the 1st quarter. Caxton Associates LP now owns 174,657 shares of the company’s stock valued at $389,000 after acquiring an additional 136,611 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Lyell Immunopharma during the 1st quarter worth $64,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Price Performance

Shares of Lyell Immunopharma stock opened at $1.03 on Thursday. Lyell Immunopharma, Inc. has a twelve month low of $0.85 and a twelve month high of $3.26. The company’s fifty day moving average is $1.20 and its 200 day moving average is $1.65.

Lyell Immunopharma (NASDAQ:LYEL) last announced its earnings results on Thursday, November 7th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.03. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The business had revenue of $0.03 million for the quarter. Analysts expect that Lyell Immunopharma, Inc. will post -0.8 EPS for the current year.

Analyst Ratings Changes

LYEL has been the subject of several research reports. Bank of America downgraded Lyell Immunopharma from a “buy” rating to an “underperform” rating and dropped their target price for the company from $6.00 to $1.00 in a research report on Wednesday, October 30th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a research note on Tuesday, November 12th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.